Last reviewed · How we verify
Carcinoma of cervix — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Bevacizumab | Bevacizumab-Bvzr | Roche | Monoclonal antibody | Vascular Endothelial Growth Factor (VEGF) | 2004-01-01 | |
| Avastin | bevacizumab | Roche | Vascular Endothelial Growth Factor Inhibitor [EPC] | Vascular endothelial growth factor A | 2004-01-01 | |
| Avastin | Avastin | Washington University School of Medicine | Vascular endothelial growth factor A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche · 2 drugs in Carcinoma of cervix
- Washington University School of Medicine · 1 drug in Carcinoma of cervix
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Carcinoma of cervix:
- Carcinoma of cervix treatment updates — RSS
- Carcinoma of cervix treatment updates — Atom
- Carcinoma of cervix treatment updates — JSON
Cite this brief
Drug Landscape (2026). Carcinoma of cervix — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/carcinoma-of-cervix. Accessed 2026-06-10.
Related
- Carcinoma of cervix full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing